Aptevo Therapeutics (NASDAQ:APVO), a clinical-stage biopharmaceutical company focused on developing novel bispecific and multispecific immunotherapies for cancer, today reported financial results for the year ended December 31, 2025, and provided a strategic business update.
The company’s fiscal year was defined by a breakthrough in its lead myeloid program and a significant strengthening of its long-term financing capabilities.
The centerpiece of the update is the clinical performance of mipletamig (APVO436), Aptevo’s lead CD123 x CD3 bispecific antibody.
In a cohort of 28 frontline acute myeloid leukemia (AML) patients, mipletamig demonstrated an 86% clinical benefit rate.
Crucially, the therapy maintained a highly favorable safety profile, with no instances of cytokine release syndrome (CRS) observed to date.
This differentiated safety data positions mipletamig as a potential best-in-class candidate in the increasingly competitive bispecific space, where severe immune-related adverse events often limit dosing and patient eligibility.
Expanding beyond its lead asset, Aptevo continued to leverage its proprietary ADAPTIR and CHELATE platforms to broaden its CD3 multispecific portfolio.
The company is actively advancing next-generation candidates designed to optimize T-cell engagement while minimizing off-target toxicities.
This platform-based approach has allowed Aptevo to target a wider range of hematologic and solid tumor indications, creating a diversified pipeline of high-value oncology assets.
Financially, Aptevo ended the year with $21.6 million in cash and cash equivalents.
To ensure continued clinical momentum, the company established a $60 million equity line of credit, providing flexible access to capital as its programs reach late-stage validation.
Management expects its current resources and available credit to fund operations into the fourth quarter of 2026.